<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902024000200091</article-id>
<article-id pub-id-type="doi">10.29262/ram.v71i2.1296</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Prevalencia de manifestaciones dermatológicas en pacientes con inmunodeficiencia común variable]]></article-title>
<article-title xml:lang="en"><![CDATA[Prevalence of dermatological manifestations in common variable immunodeficiency patients.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guendulain Velázquez]]></surname>
<given-names><![CDATA[Brenda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[O&#8217;Farrill Romanillos]]></surname>
<given-names><![CDATA[Patricia María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Alergia e Inmunología Clínica  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital de Especialidades, Centro Médico Nacional Siglo XXI Alergia e Inmunología Clínica ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2024</year>
</pub-date>
<volume>71</volume>
<numero>2</numero>
<fpage>91</fpage>
<lpage>95</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902024000200091&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902024000200091&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902024000200091&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Estimar la prevalencia de manifestaciones dermatológicas en pacientes mexicanos con inmunodeficiencia común variable.  Métodos: Estudio transversal y retrospectivo, fundamentado en el análisis de expedientes de pacientes con diagnóstico de inmunodeficiencia común variable, atendidos en el Centro Médico Nacional Siglo XXI (Instituto Mexicano del seguro Social), según los criterios de la Sociedad Europea de Inmunodeficiencias (ESID) y de los que solo 3 tenían diagnóstico genético con las siguientes mutaciones: IRF2, CTLA4 y PIK-3, ertenecientes a la Clínica de Inmunodeficiencias del Centro Médico Nacional Siglo XXI (IMSS), para evaluar las manifestaciones dermatológicas, revisión de exámenes de laboratorio: IgA, IgM, IgG y tipo de terapia de reemplazo con Inmunoglobulina. El análisis estadístico se ejecutó con el programa SPSS; para el análisis de los datos se utilizó estadística descriptiva, de acuerdo con el tipo de variable a analizar.  Resultados: Se incluyeron 36 pacientes, de los que 55.5% correspondieron a mujeres; con mediana de edad 34 años (18-94). La prevalencia de anifestaciones dermatológicas fue de 70% (n = 25). El 30.5% tuvo antecedente de dermatosis infecciosa y 39.5% dermatosis no infecciosa. La dermatosis más frecuente fue dermatitis de contacto irritativa en 13.8% de los pacientes. Todos recibieron terapia de reemplazo con inmunoglobulina humana, 33.3% por vía intravenosa y el resto por vía subcutánea.  Conclusiones: La inmunodeficiencia común variable es un error innato de la inmunidad, con diferentes manifestaciones clínicas en diversos órganos y sistemas (la piel supone uno de estos). Las manifestaciones dermatológicas no suelen describirse en pacientes con inmunodeficiencia común variable; sin embargo, es importante identificarlas por su relación con ciertas complicaciones (incremento del riesgo de sobreinfección), debido a la disrupción de la piel y terapias biológicas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objectives: Estimate the prevalence of dermatological manifestations in Mexican patients with common variable immunodeficiency.  Methods:  Cross-sectional and retrospective study, based on the analysis of records of patients with a diagnosis of common variable mmunodeficiency, treated at the Siglo XXI National Medical Center (Mexican Social Security Institute), according to the criteria of the European Society of Immunodeficiencies (ESID). and of which only 3 had a genetic diagnosis with the following mutations: IRF2, CTLA4 and PIK-3, belonging to the Immunodeficiency Clinic of the National Medical Center Siglo XXI (IMSS), to evaluate dermatological manifestations, review of laboratory tests: IgA, IgM, IgG and type of replacement therapy with Immunoglobulin. The statistical analysis was carried out with the SPSS program; Descriptive statistics were used to analyze the data, according to the type of variable to be analyzed.  Results: 36 patients were included, of which 55.5% were women; with median age 34 years (18-94). The prevalence of dermatological manifestations was 70% (n = 25). 30.5% had a history of infectious dermatosis and 39.5% had a history of non-infectious dermatosis. The most common dermatosis was irritant contact dermatitis in 13.8% of patients. All received replacement therapy with human immunoglobulin, 33.3% intravenously and the rest subcutaneously.  Conclusions: Common variable immunodeficiency is an inborn error of immunity, with different clinical manifestations in various organs and systems (the skin is one of these). Dermatological manifestations are not usually described in patients with common variable immunodeficiency; However, it is important to identify them due to their relationship with certain complications (increased risk of superinfection), due to skin disruption and biological therapies.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Inmunodeficiencia de anticuerpos]]></kwd>
<kwd lng="es"><![CDATA[Inmunodeficiencia común variable]]></kwd>
<kwd lng="es"><![CDATA[Enfermedades de la piel]]></kwd>
<kwd lng="en"><![CDATA[Antibody immunodeficiency]]></kwd>
<kwd lng="en"><![CDATA[Common variable immunodeficiency]]></kwd>
<kwd lng="en"><![CDATA[skin diseases]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chapel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lucas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Common variable immunodeficiency disorders: division into distinct clinical phenotypes]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2008</year>
<volume>112</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>277-86</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berrón-Ruiz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alteraciones inmunológicas en la inmunodeficiencia común variable]]></article-title>
<source><![CDATA[Rev Alert Mex]]></source>
<year>2017</year>
<volume>64</volume>
<page-range>87-108</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yazdani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Habibi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sharifi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Common Variable Immunodeficiency: Epidemiology, Pathogenesis, Clinical Manifestations, Diagnosis, Classification, and Management]]></article-title>
<source><![CDATA[J Investig Allergol Clin Immunol]]></source>
<year>2020</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>14-34</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wehr]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kivioja]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Schmitt]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The EUROclass trial: defining subgroups in common variable immunodeficiency]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2008</year>
<volume>111</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>77-85</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jørgensen]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Trøseid]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kummen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation]]></article-title>
<source><![CDATA[Mucosal Immunol]]></source>
<year>2016</year>
<volume>9</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1455-65</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández Romero]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Juri]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Paolini]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Malbrán]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inmunodeficiencia común variable epidemiología y manifestaciones clínicas en 69 pacientes]]></article-title>
<source><![CDATA[Medicina (Buenos Aires)]]></source>
<year>2013</year>
<volume>73</volume>
<page-range>315-23</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saikia]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Common Variable Immunodeficiency]]></article-title>
<source><![CDATA[The Indian Journal of Pediatrics]]></source>
<year>2016</year>
<volume>83</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>338-44</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cabañero-Navalon]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia-Bustos]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Nuñez-Beltran]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current clinical spectrum of common variable immunodeficiency in Spain: The multicentric nationwide GTEM-SEMICVID registry]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2022</year>
<volume>13</volume>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iglesias-Alzueta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Matamoros-Florí]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inmunodeficiencia variable común. Revisión]]></article-title>
<source><![CDATA[Allergol Immunopathol (Madr)]]></source>
<year>2001</year>
<volume>29</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>113-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>LASID Latin American Society for Immunodeficiencies</collab>
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bousfiha]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jeddane]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Picard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification]]></article-title>
<source><![CDATA[J Clin Immunol]]></source>
<year>2020</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>66-81</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soler-Palacín]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Congreso de Actualización Pediatría 2020]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tam]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Routes]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Common Variable Immunodeficiency]]></article-title>
<source><![CDATA[Am J Rhinol Allergy]]></source>
<year>2013</year>
<volume>27</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>260-5</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Driessen]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[van Zelm]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[van Hagen]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[B-cell replication history and somatic hypermutation status identify distinct pathophysiologic backgrounds in common variable immunodeficiency]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2011</year>
<volume>118</volume>
<numero>26</numero>
<issue>26</issue>
<page-range>6814-23</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Enrique-Iáñez]]></surname>
<given-names><![CDATA[Pareja]]></given-names>
</name>
</person-group>
<source><![CDATA[Inmunoglobulinas y otras moléculas de células B. Curso de Inmunología General, Departamento de Microbiología Universidad de Granada]]></source>
<year>1999</year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martinez-Gallo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Radigan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Almejún]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Pomar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Matamoros]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Cunningham-Rundles]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TACI mutations and impaired B-cell function in subjects with CVID and healthy heterozygotes]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2013</year>
<volume>131</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>468-76</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romberg]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Chamberlain]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Saadoun]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CVID-associated TACI mutations affect autoreactive B cell selection and activation]]></article-title>
<source><![CDATA[J Clin Inves]]></source>
<year>2013</year>
<volume>123</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>4283-93</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Knight]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Radigan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Toll-like receptor 7 and 9 defects in common variable immunodeficiency]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2009</year>
<volume>124</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>349-56</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graziano]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Pecoraro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mormile]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Delay in diagnosis affects the clinical outcome in a cohort of CVID patients with marked reduction of IgA serum levels]]></article-title>
<source><![CDATA[Clin Immunol]]></source>
<year>2017</year>
<volume>180</volume>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bigley]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Haniffa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Doulatov]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency]]></article-title>
<source><![CDATA[J Exper Med]]></source>
<year>2011</year>
<volume>208</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>227-34</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramos-Rodríguez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Martín-Dávila]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Garrido-Martín]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Granulomas cutáneos no infecciosos en inmunodeficiencia común variable]]></article-title>
<source><![CDATA[Rev Esp Patol]]></source>
<year>2015</year>
<page-range>159-62</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roskin]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Simchoni]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IgH sequences in common variable immune deficiency reveal altered B cell development and selection]]></article-title>
<source><![CDATA[Sci Transl Med]]></source>
<year>2015</year>
<volume>7</volume>
<numero>302</numero>
<issue>302</issue>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mouillot]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Carmagnat]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gérard]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[B-Cell and T-Cell Phenotypes in CVID Patients Correlate with the Clinical Phenotype of the Disease]]></article-title>
<source><![CDATA[J Clin Immunol]]></source>
<year>2010</year>
<volume>30</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>746-55</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zarezadeh-Mehrabadi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aghamohamadi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Abolhassani]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Aghamohammadi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comprehensive Assessment of Skin Disorders in Patients with Common Variable Immunodeficiency (CVID)]]></article-title>
<source><![CDATA[J Clin Immunol]]></source>
<year>2022</year>
<volume>42</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>653-64</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Megna]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pecoraro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Balato]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psoriasis in a cohort of patients with common variable immunodeficiency]]></article-title>
<source><![CDATA[Br J Dermatol]]></source>
<year>2019</year>
<volume>180</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>935-6</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gualdi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lougaris]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Baronio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Burden of Skin Disease in Selective IgA Deficiency and Common Variable Immunodeficiency]]></article-title>
<source><![CDATA[J Investig Allergol Clin Immunol]]></source>
<year>2015</year>
<volume>25</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>369-71</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xiao]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Miao]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gershwin]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Common variable immunodeficiency, and autoimmunity &#8211; an inconvenient truth]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2014</year>
<volume>13</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>858-64</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bergler-Czop]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Brzezi&#324;ska-Wcis&#322;o]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pyoderma gangrenosum in a patient with common variable primary immunodeficiency]]></article-title>
<source><![CDATA[Ad Dermatol Allergol]]></source>
<year>2013</year>
<volume>3</volume>
<page-range>188-91</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
